Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $862.00 Price Target at Leerink Partners

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target dropped by Leerink Partners from $980.00 to $862.00 in a research note issued to investors on Tuesday. The brokerage currently has a “market perform” rating on the biopharmaceutical company’s stock. Leerink Partners’ target price would indicate a potential upside of 23.03% from the stock’s current price.

Other analysts have also recently issued reports about the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Oppenheimer lowered their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Evercore ISI reduced their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. Bank of America reaffirmed an “underperform” rating and issued a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Finally, BMO Capital Markets reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an “overweight” rating on the stock in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $983.65.

Regeneron Pharmaceuticals Trading Up 5.1 %

Shares of NASDAQ REGN traded up $33.79 during trading on Tuesday, hitting $700.64. 541,739 shares of the company traded hands, compared to its average volume of 873,813. The firm has a market capitalization of $76.99 billion, a P/E ratio of 17.23, a P/E/G ratio of 1.60 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a 50-day moving average price of $720.81 and a 200-day moving average price of $921.72. Regeneron Pharmaceuticals has a 1 year low of $642.00 and a 1 year high of $1,211.20.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rakuten Securities Inc. grew its position in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the third quarter worth approximately $26,000. Fairfield Financial Advisors LTD bought a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $37,000. Private Wealth Management Group LLC increased its position in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 39 shares during the period. Finally, Truvestments Capital LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $39,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.